Elena Dragomir
- health economics and health outcomes of prostate cancer
- analysis of health services utilization, drug costs and clinical outcomes in patients with advanced prostate cancer
My research focuses on improving the manner in which healthcare is delivered to patients, particularly for those with prostate cancer or other urological cancers, and for finding ways to optimize cost allocation for services. Specifically, significant advances have been made in the field of prostate cancer, including new health technologies for surgery and radiation therapies for localized prostate cancers, and many innovative drugs and chemotherapies for advanced stage. Furthermore, new tests have demonstrated clinical utility and benefits in the screening, diagnosis or treatment phase of prostate cancer. Due to economic consideration or lack of cost-effectiveness evidence, many of these advances are not accessible to the general population. My research program focuses on the analysis of health service utilization and associated costs vs. benefits (clinical outcomes) from diagnosis and over the entire course of the disease in real-life settings, using administrative databases or simulation models, such as Markov models with Monte-Carlo microsimulations.